Earnings

Artelo Biosciences Says First Patient Dosed In DREAM Study Evaluating Effects Of ART27.13 In Patients With Glaucoma Or Ocular Hypertension; Initial DREAM Study Results Anticipated In Q4

Aug 10, 2026 · 08:49 AM ET· updated 1h ago

Investigator-led study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmologyInitial DREAM Study Results Anticipated in Q4 2026SOLANA BEACH, Calif., Aug. 10, 2026

Why It Matters

Artelo Biosciences started testing a new medicine called ART27.13 to see if it helps people with eye pressure problems. We'll find out if it works later this year, which shows the company is trying new ideas.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ARTL0.72

-0.00 (-0.14%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.